All free · no sign up

Tesamorelin Dosage Calculator

Calculate tesamorelin injection volumes. Pre-filled for a 2mg vial with 0.5ml BAC water (4,000 mcg/ml). Full 2mg dose = 0.5ml = 50 units.

Dose Reference Table

Pre-calculated for a 2mg vial + 0.5ml BAC water = 4,000 mcg/ml concentration. Using a 100-unit (1ml) insulin syringe.

Dose Inject Volume (ml) Syringe Units
500mcg 0.125 ml 12.5 units
1000mcg (1mg) 0.250 ml 25 units
1500mcg (1.5mg) 0.375 ml 37.5 units
2000mcg (2mg) 0.500 ml 50 units

About Tesamorelin

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that is FDA-approved under the brand name Egrifta for the treatment of HIV-associated lipodystrophy (abnormal fat distribution). It consists of the full 44 amino acid sequence of GHRH with a trans-3-hexenoic acid group added to stabilize it against enzymatic degradation.

In HIV-associated lipodystrophy, tesamorelin is used to reduce visceral (abdominal) fat accumulation. It works by stimulating the pituitary to release endogenous GH, which then promotes lipolysis in visceral adipose tissue. Beyond its FDA-approved indication, tesamorelin has been studied for body composition, cognitive function, and cardiovascular risk markers.

Tesamorelin is supplied in 2mg vials. It is reconstituted with 0.5ml of sterile diluent (or bacteriostatic water) provided with the kit, giving a concentration of 4,000 mcg/ml. The FDA-approved dose is 2mg (the full vial) administered once daily via subcutaneous injection into the abdomen.

Tesamorelin has a very short half-life of approximately 26 minutes, necessitating daily administration. It is typically injected at consistent times each day, often in the morning or at bedtime.

Frequently Asked Questions

The FDA-approved dose of tesamorelin is 2mg once daily via subcutaneous injection. For a 2mg vial + 0.5ml BAC water (4000 mcg/ml), the full dose = 0.5ml = 50 units.
Add 0.5ml of bacteriostatic water or the provided diluent to the 2mg tesamorelin vial. This gives 4000 mcg/ml. Inject slowly along the vial wall and gently swirl until dissolved. Do not shake.
In clinical trials for visceral fat reduction, significant effects were observed after 26–52 weeks of daily treatment. Short-term GH stimulation occurs rapidly given the short half-life.
Tesamorelin is administered via subcutaneous injection into the abdomen. Rotate injection sites to avoid lipodystrophy at the injection site.
Tesamorelin has been studied for visceral fat reduction, particularly in HIV lipodystrophy. Its effects on body composition in healthy individuals are being researched, but it is not FDA-approved for general weight loss.
Sermorelin Dosage GHRH analogue calculator. CJC-1295 Dosage CJC-1295 dosage calculator. Ipamorelin Dosage Ipamorelin dosage calculator. Peptide Dosage Chart Reference for all peptides.